Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0b013e318191520c
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Vinorelbine and Gemcitabine as Second- Or Third-Line Therapy for Malignant Pleural Mesothelioma

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2014English

Enhanced Cisplatin Response With Histone Acetyl Transferase Inhibitor, Anacardic Acid, in Malignant Pleural Mesothelioma Cell Line

Turkiye Klinikleri Journal of Medical Sciences
Medicine
2013English

OA08.01 Long-Term Efficacy and Safety of Nivolumab in Second- Or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Activity of PXD101, a Histone Deacetylase Inhibitor, in Preclinical Ovarian Cancer Studies

Molecular Cancer Therapeutics
Cancer ResearchOncology
2006English

Phase II Study of Cediranib in Patients With Malignant Pleural Mesothelioma: SWOG S0509

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2011English

Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) as Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Novel Therapies in Phase II and III Trials for Malignant Pleural Mesothelioma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2011English

Malignant Pleural Mesothelioma

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy